Nuveen Asset Management LLC Has $78.07 Million Position in ADMA Biologics, Inc. (NASDAQ:ADMA)

Nuveen Asset Management LLC lowered its holdings in shares of ADMA Biologics, Inc. (NASDAQ:ADMA) by 30.8% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 4,552,317 shares of the biotechnology company’s stock after selling 2,025,560 shares during the period. Nuveen Asset Management LLC owned about 1.93% of ADMA Biologics worth $78,072,000 as of its most recent SEC filing.

A number of other institutional investors have also recently bought and sold shares of the business. Commonwealth of Pennsylvania Public School Empls Retrmt SYS boosted its stake in ADMA Biologics by 1.3% during the fourth quarter. Commonwealth of Pennsylvania Public School Empls Retrmt SYS now owns 50,466 shares of the biotechnology company’s stock worth $865,000 after buying an additional 645 shares in the last quarter. Oregon Public Employees Retirement Fund boosted its stake in ADMA Biologics by 1.3% during the fourth quarter. Oregon Public Employees Retirement Fund now owns 55,600 shares of the biotechnology company’s stock worth $954,000 after buying an additional 700 shares in the last quarter. Summit Investment Advisors Inc. boosted its stake in ADMA Biologics by 3.3% during the fourth quarter. Summit Investment Advisors Inc. now owns 23,560 shares of the biotechnology company’s stock worth $404,000 after buying an additional 746 shares in the last quarter. Mutual of America Capital Management LLC boosted its stake in ADMA Biologics by 2.1% during the fourth quarter. Mutual of America Capital Management LLC now owns 35,807 shares of the biotechnology company’s stock worth $614,000 after buying an additional 751 shares in the last quarter. Finally, Maryland State Retirement & Pension System boosted its stake in ADMA Biologics by 1.1% during the fourth quarter. Maryland State Retirement & Pension System now owns 79,607 shares of the biotechnology company’s stock worth $1,365,000 after buying an additional 897 shares in the last quarter. Institutional investors and hedge funds own 75.68% of the company’s stock.

ADMA Biologics Stock Up 2.6%

Shares of NASDAQ:ADMA opened at $19.69 on Friday. The company’s fifty day moving average is $20.49 and its 200-day moving average is $18.86. The company has a debt-to-equity ratio of 0.48, a quick ratio of 3.26 and a current ratio of 7.09. ADMA Biologics, Inc. has a 52 week low of $9.22 and a 52 week high of $25.67. The company has a market capitalization of $4.70 billion, a PE ratio of 70.32 and a beta of 0.57.

ADMA Biologics (NASDAQ:ADMA) last released its quarterly earnings results on Wednesday, May 7th. The biotechnology company reported $0.14 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.16 by ($0.02). ADMA Biologics had a net margin of 17.80% and a return on equity of 53.20%. The business had revenue of $114.80 million during the quarter, compared to the consensus estimate of $116.40 million. During the same period in the prior year, the firm earned $0.08 earnings per share. The business’s quarterly revenue was up 40.2% compared to the same quarter last year. Equities research analysts predict that ADMA Biologics, Inc. will post 0.51 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

ADMA has been the topic of several recent analyst reports. StockNews.com downgraded shares of ADMA Biologics from a “hold” rating to a “sell” rating in a research note on Friday, May 9th. Cantor Fitzgerald restated an “overweight” rating and issued a $25.00 target price on shares of ADMA Biologics in a research note on Tuesday, March 4th. Finally, Raymond James boosted their target price on shares of ADMA Biologics from $25.00 to $32.00 and gave the company a “strong-buy” rating in a research note on Thursday, May 8th. One research analyst has rated the stock with a sell rating, three have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus price target of $24.25.

ADMA Biologics Profile

ADMA Biologics, Inc, a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B.